PARIS (Reuters) – French diagnostics specialist BioMrieux announced on Wednesday the launch of a new product that aims to detect within 30 minutes the presence of antibodies in those exposed to the coronavirus.
The firm said it would seek U.S. regulatory approval for its new VIDAS serology test to identify the presence of SARS-CoV-2 antibodies in infected people.
BioMerieux drew positive feedback this week from the U.S. regulator, the Food and Drug Administration (FDA), for its ‘BIOFIRE’ product to test for the virus.
(Reporting by Sudip Kar-Gupta; Editing by Clarence Fernandez)
